Scholarlink

With major advances in the technology of liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS), the proteomics analyses in Alzheimer disease (AD) have achieved unprecedented depth and breadth in the protein landscape, providing insights into mechanisms, biomarkers, and therapeutic targets of this disease. Here, we introduce progress of this technology, review major reported AD proteomics analyses, summarize potential biomarkers and drug targets, and discuss challenges and possible solutions in this LC-MS/MS-based proteomics approach. With further technical improvements and more targeted experimental designs, this approach will be a powerful tool for the discovery of biomarkers and drug targets for this devastating disease.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Proteomics for Novel Biomarker and Drug Target Discovery in Alzheimer Disease

  • 章节

  • 发表日期：

    2025年

查看全文
  • Huiming Zhu,
  • Minqi Cai,
  • Dezhu Chen,
  • Jiaojiao Sha,
  • Liangjia Du,
  • Yiqiang Chen,
  • Siyuan Liu,
  • Qian Zheng,
  • Xuefei Wei,
  • Bing Bai

摘要

With major advances in the technology of liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS), the proteomics analyses in Alzheimer disease (AD) have achieved unprecedented depth and breadth in the protein landscape, providing insights into mechanisms, biomarkers, and therapeutic targets of this disease. Here, we introduce progress of this technology, review major reported AD proteomics analyses, summarize potential biomarkers and drug targets, and discuss challenges and possible solutions in this LC-MS/MS-based proteomics approach. With further technical improvements and more targeted experimental designs, this approach will be a powerful tool for the discovery of biomarkers and drug targets for this devastating disease.